Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Nissan recalls over 480,000 vehicles in the US and Canada due to engine failure risk (AP) +++ NISSAN MOTOR Aktie +3,27%

CANTARGIA Aktie

>CANTARGIA Performance
1 Woche: 0%
1 Monat: -27,7%
3 Monate: -29,2%
6 Monate: -34,0%
1 Jahr: -80,3%
laufendes Jahr: -34,0%
>CANTARGIA Aktie
Name:  CANTARGIA AB
Land:  Schweden
Sektor:  Gesundheit
ISIN/ Wkn:  SE0006371126 / A2JAZX
Symbol/ Ticker:  7V3 (Frankfurt)
Kürzel:  FRA:7V3, ETR:7V3, 7V3:GR
Index:  -
Webseite:  https://cantargia.com/
Marktkapitalisierung:  26.39 Mio. EUR
Umsatz:  -
EBITDA:  -169.14 Mio. EUR
Gewinn je Aktie:  -0.08 EUR
Schulden:  -
Liquide Mittel:  103.93 Mio. EUR
Umsatz-/ Gewinnwachstum:  - / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 2.98 / -
Gewinnm./ Eigenkapitalr.:  - / -169.29%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  CANTARGIA
Letzte Datenerhebung:  03.07.25
>CANTARGIA Eigentümer
Aktien: 248.61 Mio. St.
f.h. Aktien: 242.7 Mio. St.
Insider Eigner: 8.07%
Instit. Eigner: 24.61%
Leerverk. Aktien: -
>CANTARGIA Peer Group

 
17.06.25 - 20:31
 Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans (Accesswire)
 
LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 mil......
11.06.25 - 20:18
 Cantargia′s Nadunolimab Aantibody Awarded US FDA Fast Track Designation (Accesswire)
 
Fast Track Designation (FTD) granted for the treatment of patients with metastatic PDAC with high IL1RAP expression levels.Reflects high unmet medical need in metastatic PDAC.Facilitates further de......
19.05.25 - 07:54
 Cantargia Publishes Promising Preclinical Results Highlighting CAN10′s Potential to Inhibit Vascular Inflammation (Accesswire)
 
IL1RAP expression positively correlates with inflammatory markers in human atherosclerotic plaques.IL1RAP blocking antibodies inhibit endothelial activation and neutrophil adhesion induced by IL-1,......
15.05.25 - 17:18
 Bulletin from the Annual General Meeting in Cantargia AB (Accesswire)
 
LUND, SWEDEN / ACCESS Newswire / May 15, 2025 / The Annual General Meeting of Cantargia (STO:CANTA) on May 15, 2025 resolved in accordance with the following:That no dividend would be paid.To disch......
13.05.25 - 07:30
 Cantargia Publishes Interim Report for the First Quarter of 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / May 13, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced its interim report for the first quarter of 2025."The fi......
12.05.25 - 08:06
 Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2 (Accesswire)
 
LUND, SE / ACCESS Newswire / May 12, 2025 / Cantargia (STO:CANTA)Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohor......
06.05.25 - 08:06
 Cantargia′s Announces Publication of Clinical Data Demonstrating Potential of Nadunolimab Plus Pembrolizumab in Solid Tumors (Accesswire)
 
LUND, SE / ACCESS Newswire / May 6, 2025 / Cantargia (STO:CANTA)Results published in the peer-reviewed journal Investigational New DrugsStudy in heavily pre-treated patients with solid tumor indica......
29.04.25 - 13:30
 Invitation to the Presentation of Cantargia′s Interim Report for Q1 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first quarter of 2025......
29.04.25 - 08:06
 Cantargia Announces Selection of Treatment Resistant Atopic Dermatitis as Second Target Indication for CAN10 (Accesswire)
 
LUND, SE / ACCESS Newswire / April 29, 2025 / Cantargia (STO:CANTA)Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets......
25.04.25 - 19:30
 Cantargia Presents Promising Preclinical Results on Anti-IL1RAP Antibody-Drug Conjugate at a Major Cancer Conference (Accesswire)
 
Anti-IL1RAP ADC demonstrated potent anti-tumor efficacy and was well tolerated in pre-clinical modelsAnti-IL1RAP ADC targets IL1RAP, which is overexpressed in many tumors and their tumor microenvir......
25.04.25 - 19:30
 Cantargia Presents Association Between Nadunolimab and Reduction of Chemotherapy Induced Peripheral Neuropathy at AACR (Accesswire)
 
LUND, SE / ACCESS Newswire / April 25, 2025 / Cantargia (STO:CANTA)Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention......
11.04.25 - 13:54
 Cantargia Publishes Annual Report 2024 (Accesswire)
 
LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced that the annual report for 2024 has been published. The......
11.04.25 - 11:30
 Notice of Annual General Meeting in Cantargia AB (Accesswire)
 
LUND, SE / ACCESS Newswire / April 11, 2025 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Thursday, 15 May 2025, at 15.00 CEST at Id......
01.04.25 - 13:54
 Cantargia appoints Morten Lind Jensen as Chief Medical Officer (Accesswire)
 
LUNDE, SE / ACCESS Newswire / April 1, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced the appointment of Morten Lind Jensen, MD, PhD, as C......
25.03.25 - 22:06
 Cantargia Publishes An Abstract On Parallel Anti-Tumor Activity And Reduction Of Chemotherapy-Induced Neuropathy With Nadunolimab (Accesswire)
 
LUND, SWEDEN / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA)Nadunolimab's additional potential in mitigating neuropathy demonstrated by data from Cantargia's CESTAFOUR and CAPAFOUR clini......
25.03.25 - 21:54
 Cantargia Presents Promising Preclinical Results on a Novel IL1RAP-Targeting Antibody-Drug Conjugate at AACR 2025 (Accesswire)
 
LUND, SE / ACCESS Newswire / March 25, 2025 / Cantargia (STO:CANTA) Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced an upcoming presentation of preclinical data on the devel......
13.03.25 - 10:30
 Cantargia to Participate at Van Lanschot Kempen′s Life Sciences Conference (Accesswire)
 
LUND, SE / ACCESS Newswire / March 13, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that members of Cantargia's management will participa......
12.03.25 - 08:09
 First Patient Enrolled in Cantargia′s Leukemia Study with nadunolimab (Accesswire)
 
LUND, SE / ACCESS Newswire / March 12, 2025 / Cantargia (STO:CANTA)Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockh......
10.03.25 - 15:30
 Cantargia′s TRIFOUR Phase 2 Study Investigating Nadunolimab in Triple Negative Breast Cancer Fully Recruited (Accesswire)
 
TRIFOUR is Cantargia's first randomized, controlled study of nadunolimabFirst preliminary efficacy results expected mid-2025 LUND, SWEDEN / ACCESS Newswire / March 10, 2025 / Cantargia (Cantargia A......
06.03.25 - 10:30
 Cantargia to Participate at H.C. Wainwright′s Annual Autoimmune & Inflammatory Virtual Conference (Accesswire)
 
LUND, SE / ACCESS Newswire / March 6, 2025 / Cantargia (STO:CANTA) Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at t......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Der guckt die Bälle weg. - Fritz Walter
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!